Introduction
Acromegaly is a rare disorder resulting from chronic hypersecretion of growth hormone (GH), mostly caused by a pituitary adenoma [1] . It mainly occurs sporadically, but may be seen in familial diseases [2] . It is characterized by dysmorphic facial and body features, anatomic and functional alterations of internal organs, metabolic, neoplastic and cardiovascular diseases (CVD), neurological symptoms and hypopituitarism secondary to adenoma mass effect, overall responsible for high morbidity and mortality [1, 3, 4] . Because of the disease complexity and the variable physician approach to patients, it is difficult to obtain a systematic assessment of the numerous complications induced by GH hypersecretion-whose risk and severity are related to disease duration and not always reversed by biochemical control-and its treatments [3, 5] and to replicate it at the various follow-ups. Moreover, because of economic restrictions imposed to the healthcare systems, a more personalized, cost-effective screening of complications would be very important in these patients.
Based on these premises, our study aimed at assessing the validity of a questionnaire purposely developed to systematically assess, at diagnosis and during follow-up, the type, prevalence and time of onset of relevant disorders typically associated with acromegaly and its treatments, to be used in the clinical practice for a patient-targeted costeffective management.
Materials and methods
Two hundred and fifty-two patients, 105 with acromegaly due to a GH-secreting adenoma (cases; 66 F; mean age 59.0 ± 14.8 years) and 147 with other types of pituitary adenoma (controls; 87 prolactinomas and 60 non-functioning adenomas, NFA; 80 F; mean age 55.0 ± 16.1 years) consecutively referred to the Division of Endocrinology, Diabetes and Metabolism, University of Turin (Italy) from November 2012 to May 2014, were evaluated.
The diagnosis of acromegaly was based on the presence of suggestive clinical features associated with MRI evidence of a pituitary adenoma, elevated age-adjusted IGF-I levels and nadir GH after oral glucose load >1 μg/l [5] . Disease was considered controlled in the presence of normal age-and gender-adjusted serum IGF-I levels and random GH < 1 μg/l during treatment and cured when these criteria were fulfilled after treatment discontinuation [5] . Prolactinoma was diagnosed in the presence of elevated serum prolactin levels and MRI evidence of pituitary adenoma, after excluding other causes of hyperprolactinemia and mixed GH-/PRL-secreting tumors. Prolactin levels at diagnosis, together with clinical, biochemical and radiological findings and (in some cases) response to therapy with dopamine agonists, contributed to differential diagnosis between prolactinomas and NFA [6] . Remission was defined as serum prolactin level in the normal range during medical treatment; patients were considered cured when prolactin levels were in the normal range after treatment discontinuation. NFA was defined as MRI-detected pituitary adenoma in the absence of hormone hypersecretion [7] . Patients with hypopituitarism were adequately substituted with hormonal replacement therapy.
Patients were asked to fill, in an outpatient setting, a self-administered, 22-item questionnaire (Acro-CQ), purposely developed to systematically assess the presence of (1) comorbidities typically associated with acromegaly and its treatment, including metabolic (glucose, lipid and bone metabolism), CVD and neoplastic disorders; intestinal diverticulosis/diverticulitis; gallbladder and kidney stones; and goiter and carpal tunnel syndrome and (2) family history of pituitary adenoma. For each comorbidity, patients were also asked to indicate their age at diagnosis, and for neoplasia, the type and location (Fig. 1) .
The choice of comorbidities to be investigated by the questionnaire was made by a team of neuroendocrinologists based on their clinical practice and expert reviews/ international guidelines: Disorders typically associated with acromegaly and deserving treatment to prevent longterm morbidity and mortality were included [3, 5, 8] . To improve patient understanding and compliance, we formulated simple and direct questions, using the easiest possible terms.
To determine Acro-CQ validity, the same data collected through questionnaire's administration were retrieved from medical records-considered the gold standard-together with information on adenoma size at diagnosis, hormonal parameters at diagnosis and follow-up (to determine disease activity and the adequacy of replacement therapy in case of hypopituitarism), the presence of residual adenoma and type and duration of the various treatments.
With regard to associated disorders ("comorbidities"), acromegaly patients had been screened at diagnosis and follow-up according to international guidelines [9] , while controls had been evaluated only in the presence of suggestive symptoms and/or risk factors. Based on the established promoting role of chronic GH hypersecretion on the development of systemic disorders and the mean reported delay in acromegaly diagnosis (2.5-10 years on average) [8] , comorbidities diagnosed ≤5 years before acromegaly were arbitrarily defined "complications", and those affecting ≥10 patients were considered "common".
Hypertension was defined as a systolic blood pressure ≥140 mmHg and/or a diastolic blood pressure ≥90 mmHg or the use of antihypertensive drugs. International criteria were applied for the diagnosis of impaired fasting glucose, impaired glucose tolerance and diabetes [10] , dyslipidemia [11] , osteopenia and osteoporosis [12] . The diagnosis of thyroid hyperplasia/goiter was established by ultrasound examination.
To confirm the concordance between self-reported disease and medical record in a different geographical setting, the study was extended to 178 patients, 78 with acromegaly and 100 with other pituitary adenomas, referred to the Pituitary Center of the Johns Hopkins University Hospital, Baltimore (USA). At this purpose, Acro-CQ, originally formulated in Italian, was translated in English and reviewed by a native speaker. Patients were contacted by mail, filled the questionnaire at home and returned it by mail using prepaid stamped envelops.
The questionnaire was returned by 35 acromegaly patients (20 F; mean age 56.1 ± 11.6 years) and 40 patients with other types of pituitary adenoma (controls; 21 F; mean Table 1 .
Have you ever been diagnosed with a benign/malignant tumour of the digestive system (esophagus
The study was approved by the Hospital Ethics Committees of both Turin University and Johns Hopkins University. Only patients able to autonomously read and fill the Have you ever been diagnosed with a haematological malignancy (lymphoma, leukaemia, myeloma) 
Statistical analysis
Prevalence of comorbidities was defined for cases and controls; in patients with acromegaly, we also calculated the prevalence, temporal distribution and median time interval between diagnosis and complication's onset. Inter-group differences were assessed using Chi-square test or Fisher's exact test (n ≤ 5); a p value <0.05 was considered statistically significant. Multivariate logistic regression analysis, adjusted for gender and age at time of response to the questionnaire, was performed to test differences in prevalence of comorbidities between groups; odds ratios were also calculated. The concordance between clinical record and questionnaire was evaluated by Cohen's Kappa coefficient [13] : For k ≤ 0.6, logistic regression was performed to assess the influence of gender and age at evaluation (independent predictors of the model) on questionnaire response. Gender differences in answering to the questionnaire were calculated by Fisher's exact test. Statistical analysis was performed with STATA Statistical Software, release 12 (StataCorp LP, College Station, TX, USA).
Results
The groups of patients with acromegaly and controls from Italy and USA were homogeneous for gender and age distribution, at diagnosis of pituitary adenoma and at evaluation (Table 1) .
Neoplasia was more frequently associated with acromegaly than other pituitary adenomas, although the statistical significance was reached only for gastrointestinal (p < 0.004; p < 0.0001 for colonic polyposis) and genitourinary neoplasia (p < 0.01) (Supplementary Table 1 ). The great majority of the tumors, except for hematologic ones, were benign, as detailed in Table 2 .
Acromegaly patients were at higher risk of metabolic abnormalities (impaired glucose tolerance; IGT/diabetes; dyslipidemia; osteopenia/osteoporosis), hypertension, hypertrophic/dilatative and valvular cardiac disorders (p < 0.0005), but not for arrhythmias, ischemic events or aneurysms. Gallbladder (p < 0.0001) and kidney stones (p < 0.004), intestinal diverticulosis (p < 0.0001), goiter (p < 0.0001), obstructive sleep apnea (p = 0.004) and carpal tunnel syndrome (p < 0.0001) were also more frequent in acromegaly. The majority of complications appeared soon after acromegaly diagnosis (median ≤ 5.5 years) (Supplementary Table 1 ). In both groups, patients typically developed gallbladder and kidney stones during SSA treatment (Supplementary Table 1) .
Familial history of pituitary adenoma was present in four patients with acromegaly and one with NFA (4/5 were males).
In the Italian cohort, questionnaires were completely filled by 98.9 % of acromegaly patients, and by 95.7 % of the controls; only one item (typically diverticulosis, IGT/ diabetes and genitourinary benign neoplasia) was missing in incomplete questionnaires (Supplementary Table 2) .
Concordance between questionnaire and medical record was good or excellent (k > 0.6) for all items in both groups, except for genitourinary neoplasia (k = 0.54), CVD (k = 0.45) and dyslipidemia (k = 0.51), underreported in acromegaly. Logistic regression analysis showed a higher number of mismatches in males for genitourinary benign neoplasia, but no gender differences for CVD and dyslipidemia. Concordance between questionnaire and medical record was negatively associated with age at the time of questionnaire's compilation for genitourinary benign neoplasia, CVD and IGT.
The administration of Acro-CQ to the Baltimore cohort confirmed the excellent rate of e-questionnaire completion (97 % in acromegaly and 97.7 % in controls of the returned questionnaires were completely filled), as well the high concordance between questionnaire and medical record, being k > 0.7 for all items except for thyroid hyperplasia (k = 0.4), underreported in the control group.
Discussion
We present the results of a cross-sectional study assessing the validity of Acro-CQ, the first questionnaire developed to systematically assess at diagnosis, and monitor during follow-up, the presence of comorbidities typically associated with acromegaly, thus improving patient management. Acromegaly is a chronic disease associated with a large number of comorbidities, typically presenting in the first years after diagnosis and not always reversed after disease control, responsible for a significant increase in morbidity, impairment of the quality of life and high mortality rate [1, [3] [4] [5] . At the same time, due to the disease complexity and variable physician approach to patients, it is currently difficult to obtain a systematic evaluation at diagnosis to be replicated at followups. Moreover, because of economic restrictions imposed on the healthcare systems, a more personalized monitoring of complications would be extremely important for a cost-effective patient management. For this purpose, historical information retrieved from patients through validated tools could be extremely useful, especially for those with limited available medical data evaluated in specialized medical centers geographically far from their residence and referring physicians. According to our data, Acro-CQ is a valid tool for an easy, comprehensive and inexpensive assessment and monitoring of acromegaly comorbidities. Indeed, the patient acceptance rate and concordance with medical record are very high, independently from patient age, gender, language and clinical setting. The success of the questionnaire is likely based on the clear format, close-ended questions with dichotomous answers formulated using an easy and straightforward language [14, 15] . When questionnaire was mailed, the percentage of return was overall satisfactory (42 %). Providing patients with prepaid stamped envelops may have increased the rate of response [16] .
On the other hand, a minor limitation to the clinical application of the questionnaire at each follow-up visits could be the relatively long time needed to completely fill the questionnaire in patients with many comorbidities.
Moreover, being the questionnaire self-administered, we demonstrated for the first time that patients with acromegaly and, more generally, pituitary adenomas are highly aware about disorders associated with their condition.
Finally, using both questionnaires and medical records, the prevalence data of a great variety of disorders were retrieved from a large and homogeneous cohort of patients with acromegaly, for the first time compared to patients with other types of pituitary adenoma. Data analysis demonstrated a significantly higher prevalence of metabolic and cardiovascular disorders, as well as thyroid hyperplasia, carpal tunnel syndrome and intestinal diverticulosis in acromegaly than in other pituitary adenomas, confirming percentages obtained from previous studies considering acromegaly patients per se, or in comparison with healthy subjects [3, [17] [18] [19] [20] [21] [22] . On the contrary, the prevalence of obstructive sleep apnea was lower in our cohort than previously reported (19 vs. 60-90 %) [3] , underling the importance of formal assessment of sleep disorders, as symptoms leading to polysomnography investigation are frequently underestimated.
Independently of the type of pituitary adenoma, a strong association was found between SSA therapy and the development of gallstones (confirming the literature data [23] ) and kidney stones. Several mechanisms for which SSA contribute to gallstones formation have been postulated, leading to increased bile concentration and lithogenic changes in its composition, together with physical conditions favoring micro-crystal precipitation and stone formation. Conversely, mechanisms that could cause SSA to predispose to kidney stones formation remain unknown, as chronic administration of SSA apparently does not impact on calcium metabolism [24] .
Whether the risk of cancer and related mortality is increased by GH hypersecretion is debated [3, 20, 21, 25] . We found that the prevalence of neoplasia in acromegaly was not significantly higher than in other pituitary adenomas, except for gastrointestinal and genitourinary tumors (Supplementary Table 1) , being the great majority of these lesions benign ( Table 2) . Rates of thyroid hyperplasia, gastrointestinal and genitourinary benign tumors were in line with the literature [3, 21, 26 ], but we did not observe the increased risk of malignant transformation of thyroid nodules and intestinal polyps reported by larger cohort studies and meta-analysis [3, 20, 21, 25] , possibly due to the smaller sample size.
In conclusion, we recommend Acro-CQ for an easy, inexpensive, reproducible and comprehensive assessment of relevant comorbidities associated with acromegaly (but also with other pituitary adenomas), at diagnosis and follow-up visits, to guide a patient-targeted and cost-effective management. Because it takes a relatively long time to completely fill the questionnaire in patients with many comorbidities, physicians could decide in more complex patients, especially those requiring very frequent visits, to administer the Acro-CQ only during selected follow-up visits.
The Acro-CQ can also be used to retrieve data for survey studies in the field of pituitary disorders, as clinical information is easily and rapidly accessible for statistical analysis.
The application of this tool to larger cohorts of patients (i.e., multicenter studies) would be extremely useful to better determine the validity of the suggested tool, both in the clinical and research settings.
